Drugs / PF-06755992
last change Mar 2023 re-read 2 minutes ago

PF-06755992

Developed for
prostate neoplasm
Investigated by
Pfizer

Trials 1 · a red edge is where a trial was stopped

20162017201820192020202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT02616185 Dec 2015 → Feb 2021 prostate neoplasm Pfizer Terminated No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as PF-06755992 ClinicalTrials.gov intervention name — accepted as the source's own label NCT02616185
Route Intramuscular “patients with mCRPC received intramuscular PrCa VBIR” PMID 36948505 Mar 2023